Global Dapagliflozin Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Dapagliflozin Market Analysis

  • Pharmaceutical
  • Upcoming Report
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

The global dapagliflozin market is driven by the increasing prevalence of diabetes, heart failure, and chronic kidney disease (CKD). According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20-79 were living with diabetes in 2021, with the number expected to rise to 643 million by 2030. Furthermore, heart failure affects over 64 million people globally, with nearly half showing reduced ejection fraction, a key indication for dapagliflozin use. Chronic kidney disease impacts nearly 10% of the global population, with millions remaining undiagnosed due to asymptomatic progression. The efficacy of dapagliflozin in managing glucose levels, reducing cardiovascular risks, and slowing CKD progression has positioned it as a critical therapeutic agent, particularly in regions with a high burden of these conditions, such as Asia-Pacific and North America.

Filled Map Analysis

Frequently Asked Questions

The market is segmented based on Segmentation, By Indication (Type 2 Diabetes Mellitus, Heart Failure (HFrEF), and Chronic Kidney Disease (CKD)), Dosage Strength (5 mg and 10 mg), Application (Monotherapy and Combination Therapy), Age Group (Adult and Geriatric), End User (Hospitals, Specialty Clinics, and Homecare Settings), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032 .
The Global Dapagliflozin Market size was valued at USD 3.21 USD Billion in 2024.
The Global Dapagliflozin Market is projected to grow at a CAGR of 6.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.